OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

M. C. Genovese; A. Lertratanakul; J. Anderson; K. Papp; W. Tillett; F. Van den Bosch; S. Tsuji; E. Dokoupilova; M. Keiserman; X. Wang; S. Zhong; P. Zueger; A. Pangan; P. J. Mease

Journal ArticleOPEN ACCESS

OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

Genovese M
Lertratanakul A
Anderson J
et al.

Annals of the Rheumatic Diseases (2020) 79(Suppl 1) 139-139

DOI: 10.1136/annrheumdis-2020-eular.1229

N/ACitations

19Readers

Abstract

Background: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved

Cite

CITATION STYLE

APA

Genovese, M. C., Lertratanakul, A., Anderson, J., Papp, K., Tillett, W., Van den Bosch, F., … Mease, P. J. (2020). OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL. Annals of the Rheumatic Diseases, 79(Suppl 1), 139–139. https://doi.org/10.1136/annrheumdis-2020-eular.1229

OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

Abstract

Cite

Register to see more suggestions